Based on the AENEAS study, aumolertinib was approved in China as a first-line therapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions (19del) or L858R mutations in December 2021. Here, EGFR is linked to non-small cell lung carcinoma.